Federal (United States) · Statute compilation
Title III
55 sections
55 sections
- Pub. L. 114-255, div. A, tit. III, subtit. A, sec. 3001 (as amended)PATIENT EXPERIENCE DATA.
- Pub. L. 114-255, div. A, tit. III, subtit. A, sec. 3002 (as amended)PATIENT-FOCUSED DRUG DEVELOPMENT GUIDANCE.
- Pub. L. 114-255, div. A, tit. III, subtit. A, sec. 3003 (as amended)STREAMLINING PATIENT INPUT.
- Pub. L. 114-255, div. A, tit. III, subtit. A, sec. 3004 (as amended)REPORT ON PATIENT EXPERIENCE DRUG DEVELOPMENT.
- Pub. L. 114-255, div. A, tit. III, subtit. B, sec. 3011 (as amended)QUALIFICATION OF DRUG DEVELOPMENT TOOLS.
- Pub. L. 114-255, div. A, tit. III, subtit. B, sec. 3012 (as amended)TARGETED DRUGS FOR RARE DISEASES.
- Pub. L. 114-255, div. A, tit. III, subtit. B, sec. 3013 (as amended)REAUTHORIZATION OF PROGRAM TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES.
- Pub. L. 114-255, div. A, tit. III, subtit. B, sec. 3014 (as amended)GAO STUDY OF PRIORITY REVIEW VOUCHER PROGRAMS.
- Pub. L. 114-255, div. A, tit. III, subtit. B, sec. 3015 (as amended)AMENDMENTS TO THE ORPHAN DRUG GRANTS.
- Pub. L. 114-255, div. A, tit. III, subtit. B, sec. 3016 (as amended)NATIONAL CENTERS OF EXCELLENCE IN ADVANCED AND CONTINUOUS PHARMACEUTICAL MANUFACTURING.
- Pub. L. 114-255, div. A, tit. III, subtit. C, sec. 3021 (as amended)NOVEL CLINICAL TRIAL DESIGNS.
- Pub. L. 114-255, div. A, tit. III, subtit. C, sec. 3022 (as amended)REAL WORLD EVIDENCE.
- Pub. L. 114-255, div. A, tit. III, subtit. C, sec. 3023 (as amended)PROTECTION OF HUMAN RESEARCH SUBJECTS.
- Pub. L. 114-255, div. A, tit. III, subtit. C, sec. 3024 (as amended)INFORMED CONSENT WAIVER OR ALTERATION FOR CLINICAL INVESTIGATIONS.
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3031 (as amended)SUMMARY LEVEL REVIEW.
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3032 (as amended)EXPANDED ACCESS POLICY.
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3033 (as amended)ACCELERATED APPROVAL FOR REGENERATIVE ADVANCED THERAPIES.
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3034 (as amended)GUIDANCE REGARDING DEVICES USED IN THE RECOVERY, ISOLATION, OR DELIVERY OF REGENERATIVE ADVANCED THERAPIES.
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3035 (as amended)REPORT ON REGENERATIVE ADVANCED THERAPIES.
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3036 (as amended)STANDARDS FOR REGENERATIVE MEDICINE AND REGENERATIVE ADVANCED THERAPIES.
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3037 (as amended)HEALTH CARE ECONOMIC INFORMATION.
- Pub. L. 114-255, div. A, tit. III, subtit. D, sec. 3038 (as amended)COMBINATION PRODUCT INNOVATION.
- Pub. L. 114-255, div. A, tit. III, subtit. E, sec. 3041 (as amended)ANTIMICROBIAL RESISTANCE MONITORING.
- Pub. L. 114-255, div. A, tit. III, subtit. E, sec. 3042 (as amended)LIMITED POPULATION PATHWAY.
- Pub. L. 114-255, div. A, tit. III, subtit. E, sec. 3043 (as amended)PRESCRIBING AUTHORITY.
- Pub. L. 114-255, div. A, tit. III, subtit. E, sec. 3044 (as amended)SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA FOR MICROORGANISMS; ANTIMICROBIAL SUSCEPTIBILITY TESTING DEVICES.
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3051 (as amended)BREAKTHROUGH DEVICES.
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3052 (as amended)HUMANITARIAN DEVICE EXEMPTION.
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3053 (as amended)RECOGNITION OF STANDARDS.
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3054 (as amended)CERTAIN CLASS I AND CLASS II DEVICES.
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3055 (as amended)CLASSIFICATION PANELS.
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3056 (as amended)INSTITUTIONAL REVIEW BOARD FLEXIBILITY.
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3057 (as amended)CLIA WAIVER IMPROVEMENTS.
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3058 (as amended)LEAST BURDENSOME DEVICE REVIEW.
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3059 (as amended)CLEANING INSTRUCTIONS AND VALIDATION DATA REQUIREMENT.
- Pub. L. 114-255, div. A, tit. III, subtit. F, sec. 3060 (as amended)CLARIFYING MEDICAL SOFTWARE REGULATION.
- Pub. L. 114-255, div. A, tit. III, subtit. G, sec. 3071 (as amended)SILVIO O. CONTE SENIOR BIOMEDICAL RESEARCH AND BIOMEDICAL PRODUCT ASSESSMENT SERVICE.
- Pub. L. 114-255, div. A, tit. III, subtit. G, sec. 3072 (as amended)HIRING AUTHORITY FOR SCIENTIFIC, TECHNICAL, AND PROFESSIONAL PERSONNEL.
- Pub. L. 114-255, div. A, tit. III, subtit. G, sec. 3073 (as amended)ESTABLISHMENT OF FOOD AND DRUG ADMINISTRATION INTERCENTER INSTITUTES.
- Pub. L. 114-255, div. A, tit. III, subtit. G, sec. 3074 (as amended)SCIENTIFIC ENGAGEMENT.
- Pub. L. 114-255, div. A, tit. III, subtit. G, sec. 3075 (as amended)DRUG SURVEILLANCE.
- Pub. L. 114-255, div. A, tit. III, subtit. G, sec. 3076 (as amended)REAGAN-UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION.
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3081 (as amended)MEDICAL COUNTERMEASURE GUIDELINES.
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3082 (as amended)CLARIFYING BARDA CONTRACTING AUTHORITY.
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3083 (as amended)COUNTERMEASURE BUDGET PLAN.
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3084 (as amended)MEDICAL COUNTERMEASURES INNOVATION.
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3085 (as amended)STREAMLINING PROJECT BIOSHIELD PROCUREMENT.
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3086 (as amended)ENCOURAGING TREATMENTS FOR AGENTS THAT PRESENT A NATIONAL SECURITY THREAT.
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3087 (as amended)PAPERWORK REDUCTION ACT WAIVER DURING A PUBLIC HEALTH EMERGENCY.
- Pub. L. 114-255, div. A, tit. III, subtit. H, sec. 3088 (as amended)CLARIFYING FOOD AND DRUG ADMINISTRATION EMERGENCY USE AUTHORIZATION.
- Pub. L. 114-255, div. A, tit. III, subtit. I, sec. 3091 (as amended)PREDICTABLE REVIEW TIMELINES OF VACCINES BY THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES.
- Pub. L. 114-255, div. A, tit. III, subtit. I, sec. 3092 (as amended)REVIEW OF PROCESSES AND CONSISTENCY OF ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES RECOMMENDATIONS.
- Pub. L. 114-255, div. A, tit. III, subtit. I, sec. 3093 (as amended)ENCOURAGING VACCINE INNOVATION.
- Pub. L. 114-255, div. A, tit. III, subtit. J, sec. 3101 (as amended)TECHNICAL CORRECTIONS.
- Pub. L. 114-255, div. A, tit. III, subtit. J, sec. 3102 (as amended)COMPLETED STUDIES.